Literature DB >> 21622209

JAK-STAT signaling in hepatic fibrosis.

Markus Mair1, Leander Blaas, Christoph H Österreicher, Emilio Casanova, Robert Eferl.   

Abstract

Chronic liver injury, liver fibrosis and formation of hepatocellular carcinoma are intimately linked and represent a major medical challenge since treatment options are limited. Therefore, it is important to identify cellular and molecular pathways that promote liver damage or provide hepatoprotection for development of therapeutic approaches. Recently, the transcription factors STAT3 and STAT5 have been implicated in liver fibrosis induced by cholestatic liver damage. In this review, we summarize our current knowledge about STAT proteins in liver fibrosis and focus on common activities that underlie the hepatoprotective mechanisms regulated by IL-6/gp130/STAT3 and GH/STAT5/IGF-1 signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21622209     DOI: 10.2741/3886

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  24 in total

1.  Adiponectin modulates focal adhesion disassembly in activated hepatic stellate cells: implication for reversing hepatic fibrosis.

Authors:  Pradeep Kumar; Tekla Smith; Khalidur Rahman; Jamie E Mells; Natalie E Thorn; Neeraj K Saxena; Frank A Anania
Journal:  FASEB J       Date:  2014-08-25       Impact factor: 5.191

Review 2.  Force Matters: Biomechanical Regulation of Cell Invasion and Migration in Disease.

Authors:  FuiBoon Kai; Hanane Laklai; Valerie M Weaver
Journal:  Trends Cell Biol       Date:  2016-04-04       Impact factor: 20.808

Review 3.  STAT3 in hepatocellular carcinoma: new perspectives.

Authors:  Jasmin Svinka; Wolfgang Mikulits; Robert Eferl
Journal:  Hepat Oncol       Date:  2013-12-20

4.  JAK Kinase Inhibitors as Possible Treatment for Myeloproliferative Disorders and Cancer: Patent Highlight.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2012-07-05       Impact factor: 4.345

Review 5.  STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver.

Authors:  Bin Gao; Hua Wang; Fouad Lafdil; Dechun Feng
Journal:  J Hepatol       Date:  2012-04-12       Impact factor: 25.083

Review 6.  Inflammation and liver tumorigenesis.

Authors:  Beicheng Sun; Michael Karin
Journal:  Front Med       Date:  2013-05-17       Impact factor: 4.592

7.  Open chromatin profiling in mice livers reveals unique chromatin variations induced by high fat diet.

Authors:  Amy Leung; Brian W Parks; Juan Du; Candi Trac; Ryan Setten; Yin Chen; Kevin Brown; Aldons J Lusis; Rama Natarajan; Dustin E Schones
Journal:  J Biol Chem       Date:  2014-07-08       Impact factor: 5.157

8.  Distinctive pharmacological differences between liver cancer cell lines HepG2 and Hep3B.

Authors:  Guo-Hua Qiu; Xiaojin Xie; Fang Xu; Xiaohao Shi; Yue Wang; Linhong Deng
Journal:  Cytotechnology       Date:  2014-07-08       Impact factor: 2.058

Review 9.  JAK-STAT in lipid metabolism of adipocytes.

Authors:  Dong Xu; Chunyan Yin; Sisi Wang; Yanfeng Xiao
Journal:  JAKSTAT       Date:  2013-12-06

10.  Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis.

Authors:  Patricia Stiedl; Robert McMahon; Leander Blaas; Victoria Stanek; Jasmin Svinka; Beatrice Grabner; Gernot Zollner; Sonja M Kessler; Thierry Claudel; Mathias Müller; Wolfgang Mikulits; Martin Bilban; Harald Esterbauer; Robert Eferl; Johannes Haybaeck; Michael Trauner; Emilio Casanova
Journal:  Hepatology       Date:  2015-02       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.